1027671-54-0Relevant academic research and scientific papers
IN VIVO ENGINEERED CEREBLON PROTEIN
-
Paragraph 0242, (2020/07/15)
Disclosed herein are in vivo engineered cereblon protein and methods of making the same. The in vivo engineered cereblon protein can include a site-specific non-naturally occurring modification at cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO: 2 or 3, the modification comprising a moiety resulting from an in vivo Michael addition reaction between an exogenous Michael acceptor and the cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO: 2 or 3.
4-(Phenylsulfonyl)piperidines: Novel, selective, and bioavailable 5-HT2A receptor antagonists
Fletcher, Stephen R.,Burkamp, Frank,Blurton, Peter,Cheng, Susan K. F.,Clarkson, Robert,O'Connor, Desmond,Spinks, Daniel,Tudge, Matthew,Van Niel, Monique B.,Patel, Smita,Chapman, Kerry,Marwood, Rose,Shepheard, Sara,Bentley, Graham,Cook, Gina P.,Bristow, Linda J.,Castro, Jose L.,Hutson, Peter H.,MacLeod, Angus M.
, p. 492 - 503 (2007/10/03)
On the basis of a spirocyclic ether screening lead, a series of acyclic sulfones have been identifed as high-affinity, selective 5-HT2A receptor antagonists. Bioavailability lacking in the parent, 1-(2-(2,4-difluorophenyl)ethyl)-4-(phenylsulfon
